Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Open-label Study of Amivantamab in Previously Treated Advanced or Metastatic Gastric or Esophageal Cancer
jRCT2031210198Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2021
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of amivantamab in gastric cancer (GC), esophagogastric junction cancer and esophageal cancer (2 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoint: Objective Response Rate (ORR). Started Sep 2021; status: completed.
02
Drugs
amivantamab
03
Conditions
gastric cancer (GC)esophagogastric junction canceresophageal cancer
Beyond the preview
Go deeper on jRCT2031210198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210198.